H. G. Pars Laboratories, Inc.

Lexington, MA 02173

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $0.0
First Award Date 03/01/85
Most Recent Award Date 09/01/85

Key Personnel

Last Name Name Awards Contact
Meltzer Peter C Meltzer 1
Duffy Eric P Duffy 1
Pars Harry G Pars 3

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/85 - 11/15/86

An effective oral male antifertility agent, which is both non-toxic and reversible, is not currently available. Gossypol, the most promising non-steroidal male antifertility lead, has an unacceptably narrow therapeutic ratio. We propose that the therapeutic ratio may be improved by alteration of the pharmaco-kinetics and bioavailability throug...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/85 - 02/29/88

At the present time there is no medication available to patients with moderate to severe pain with the following characteristics: No physical drug dependence liability, little or no oral or overdose lethality, little or no effects on respiratory centers, orally potent, and long acting. In this project we propose to prepare and pharamacological...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/85 - 04/30/86

H. G. Pars Pharmaceutical Laboratories' long-term goal is to develop and market an orally active antihypertensive drug from its series of sulfur and nitrogen cannabinoid analogs. Hypotensive cannabinoids are believed to exert their effects by altering central sympathetic nervous system activity but the exact mechanism of action is not known and...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/85 - 04/30/86

The modification of beta-lactam antibiotics continues to be a promising means for the improvement of this very important class of antimicrobials. The varied useful attributes of the new oxacephalosporin moxalactam, namely broad spectrum of activity, favorable pharmacokinetic profile, and stability, prompts us to propose the synthesis and evaluat...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/85 - 08/31/85

Current bacteriocidal and fungicidal agents are unsatisfactory for use on sensitive soft tissue or mucous membrane. There is no known chemical agent which possesses broad range bacteriocidal and fungicidal activity and is nonirritant towards ocular tissue. The discovery of such an agent would be useful for such divergent purposes as sterilizat...